The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities
Open accessAbstract
Despite molecular and clinical heterogeneity, small cell lung cancer (SCLC) is treated as a single entity with predictably poor results. Using tumor expression data and non-negative matrix factorization, we identify four SCLC subtypes defined largely by differential expression of transcription factors ASCL1, NEUROD1, and POU2F3 or low expression of all three transcription factor signatures accompanied by an Inflamed gene signature (SCLC-A, N, P and I, respectively). SCLC-I experiences the greatest benefit from the addition of immunotherapy to chemotherapy, while the other subtypes each have distinct vulnerabilities, including to inhibitors of PARP, Aurora kinases, or BCL-2. Cisplatin treatment of SCLC-A patient-derived xenografts induces intratumoral shifts toward SCLC-I, supporting subtype switching as a mechanism of acquired platinum resistance. We propose that matching baseline tumor subtype to therapy, as well as manipulating subtype switching on therapy, may enhance depth and duration of response for SCLC patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Robust enumeration of cell subsets from tissue expression profiles
Newman, A. M., Liu, C. L., Green, M. R., Gentles, A. J., Feng, W., Xu, Y., Hoang, C. D., Diehn, M., & Alizadeh, A. A. (2015) · Nature Methods · doi:10.1038/nmeth.3337 · Cited by 13,224
Integrating single-cell transcriptomic data across different conditions, technologies, and species
Butler, A., Hoffman, P., Smibert, P., Papalexi, E., & Satija, R. (2018) · Nature Biotechnology · doi:10.1038/nbt.4096 · Cited by 13,174
Determining cell type abundance and expression from bulk tissues with digital cytometry
Newman, A. M., Steen, C. B., Liu, C. L., Gentles, A. J., Chaudhuri, A. A., Scherer, F., Khodadoust, M. S., Esfahani, M. S., Luca, B. A., Steiner, D., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0114-2 · Cited by 4,478
La Manno, G., Soldatov, R., Zeisel, A., Braun, E., Hochgerner, H., Petukhov, V., Lidschreiber, K., Kastriti, M. E., Lönnerberg, P., Furlan, A., et al. (2018) · Nature · doi:10.1038/s41586-018-0414-6 · Cited by 4,118
Molecular and genetic properties of tumors associated with local immune cytolytic activity
Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G., & Hacohen, N. (2015) · Cell · doi:10.1016/j.cell.2014.12.033 · Cited by 3,825
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
Ayers, M., Lunceford, J., Nebozhyn, M., Murphy, E., Loboda, A., Kaufman, D. R., Albright, A., Cheng, J. D., Kang, S. P., Shankaran, V., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci91190 · Cited by 3,788
First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer
Horn, L., Mansfield, A. S., Szczęsna, A., Havel, L., Krzakowski, M., Hochmair, M. J., Huemer, F., Losonczy, G., Johnson, M. L., Nishio, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809064 · Cited by 3,586
Self-citationComprehensive genomic profiles of small cell lung cancer
George, J., Lim, J. S., Jang, S. J., Cun, Y., Ozretić, L., Kong, G., Leenders, F., Lu, X., Fernández-Cuesta, L., Bosco, G., et al. (2015) · Nature · doi:10.1038/nature14664 · Cited by 2,340
Paz-Ares, L., Dvorkin, M., Chen, Y., Reinmuth, N., Hotta, K., Trukhin, D., Statsenko, G., Hochmair, M. J., Özgüroğlu, M., Ji, J. H., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32222-6 · Cited by 2,298
Wolf, F. A., Hamey, F. K., Plass, M., Solana, J., Dahlin, J. S., Göttgens, B., Rajewsky, N., Simon, L., & Theis, F. J. (2019) · Genome Biology · doi:10.1186/s13059-019-1663-x · Cited by 1,698
Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data
Rudin, C. M., Poirier, J. T., Byers, L. A., Dive, C., Dowlati, A., George, J., Heymach, J. V., Johnson, J. E., Lehman, J. M., MacPherson, D., et al. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0133-9 · Cited by 1,254
Self-citationAntonia, S. J., López-Martin, J. A., Bendell, J., Ott, P. A., Taylor, M., Eder, J. P., Jäger, D., Pietanza, M. C., Le, D. T., de Braud, F., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30098-5 · Cited by 1,244
Byers, L. A., Diao, L., Wang, J., Saintigny, P., Girard, L., Peyton, M., Shen, L., Fan, Y., Giri, U., Tumula, P. K., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1558 · Cited by 1,059
Self-citationOtt, P. A., Bang, Y.-J., Piha-Paul, S. A., Razak, A. R. A., Bennouna, J., Soria, J.-C., Rugo, H. S., Cohen, R. B., O’Neil, B. H., Mehnert, J. M., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.2276 · Cited by 969
Skoulidis, F., Byers, L. A., Diao, L., Papadimitrakopoulou, V. A., Tong, P., Izzo, J., Behrens, C., Kadara, H., Parra, E. R., Canales, J. R., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1236 · Cited by 936
Self-citationSen, T., Rodriguez, B. L., Chen, L., Corte, C. M. D., Morikawa, N., Fujimoto, J., Cristea, S., Nguyen, T., Diao, L., Li, L., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1020 · Cited by 902
Self-citation(1986) · Lung Cancer · doi:10.1016/s0169-5002(86)80023-x · Cited by 900
Hellmann, M. D., Callahan, M. K., Awad, M. M., Calvo, E., Ascierto, P. A., Atmaca, A., Rizvi, N. A., Hirsch, F. R., Selvaggi, G., Szustakowski, J. D., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.04.001 · Cited by 893
Pantelidou, C., Sonzogni, O., De Oliveria Taveira, M., Mehta, A. K., Kothari, A., Wang, D., Visal, T., Li, M. K., Pinto, J., Castrillon, J. A., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1218 · Cited by 743
Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer
Hodgkinson, C. L., Morrow, C. J., Li, Y., Metcalf, R. L., Rothwell, D. G., Trapani, F., Polanski, R., Burt, D. J., Simpson, K. L., Morris, K., et al. (2014) · Nature Medicine · doi:10.1038/nm.3600 · Cited by 694
Small cell lung cancer: Where do we go from here?
Byers, L. A., & Rudin, C. M. (2015) · Cancer · doi:10.1002/cncr.29098 · Cited by 636
Self-citationMollaoglu, G., Guthrie, M. R., Böhm, S., Brägelmann, J., Can, I., Ballieu, P. M., Marx, A., George, J., Heinen, C., Chalishazar, M. D., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2016.12.005 · Cited by 588
Self-citationRudin, C. M., Hann, C. L., Garon, E. B., Ribeiro de Oliveira, M., Bonomi, P. D., Camidge, D. R., Chu, Q., Giaccone, G., Khaira, D., Ramalingam, S. S., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3090 · Cited by 564
Byers, L. A., Wang, J., Nilsson, M. B., Fujimoto, J., Saintigny, P., Yordy, J., Giri, U., Peyton, M., Fan, Y. H., Diao, L., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0112 · Cited by 557
Self-citationMak, M. P., Tong, P., Diao, L., Cardnell, R. J., Gibbons, D. L., William, W. N., Skoulidis, F., Parra, E. R., Rodriguez-Canales, J., Wistuba, I. I., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0876 · Cited by 535
Self-citationSuppression of STING Associated with LKB1 Loss in KRAS-Driven Lung Cancer
Kitajima, S., Ivanova, E., Guo, S., Yoshida, R., Campisi, M., Sundararaman, S. K., Tange, S., Mitsuishi, Y., Thai, T. C., Masuda, S., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0689 · Cited by 526
Baine, M. K., Hsieh, M.-S., Lai, W. V., Egger, J. V., Jungbluth, A. A., Daneshbod, Y., Beras, A., Spencer, R., Lopardo, J., Bodd, F., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.09.009 · Cited by 522
Ireland, A. S., Micinski, A. M., Kastner, D. W., Guo, B., Wait, S. J., Spainhower, K. B., Conley, C. C., Chen, O. S., Guthrie, M. R., Soltero, D., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.05.001 · Cited by 508
Borromeo, M. D., Savage, T. K., Kollipara, R. K., He, M., Augustyn, A., Osborne, J. K., Girard, L., Minna, J. D., Gazdar, A. F., Cobb, M. H., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.06.081 · Cited by 503
Self-citationIntratumoural heterogeneity generated by Notch signalling promotes small-cell lung cancer
Lim, J. S., Ibaseta, A., Fischer, M. M., Cancilla, B., O’Young, G., Cristea, S., Luca, V. C., Yang, D., Jahchan, N. S., Hamard, C., et al. (2017) · Nature · doi:10.1038/nature22323 · Cited by 485
Gazdar, A. F., Carney, D. N., Nau, M. M., & Minna, J. D. (1985) · PubMed · Cited by 477
Self-citationParkes, E. E., Walker, S. M., Taggart, L. E., McCabe, N., Knight, L. A., Wilkinson, R., McCloskey, K. D., Buckley, N. E., Savage, K. I., Salto-Tellez, M., et al. (2017) · Journal of the National Cancer Institute · doi:10.1093/jnci/djw199 · Cited by 462
POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer
Huang, Y.-H., Klingbeil, O., He, X.-Y., Wu, X. S., Arun, G., Lu, B., Somerville, T. D. D., Milazzo, J. P., Wilkinson, J. E., Demerdash, O. E., et al. (2018) · Genes & Development · doi:10.1101/gad.314815.118 · Cited by 422
Chung, H. C., Piha-Paul, S. A., Lopez-Martin, J., Schellens, J. H. M., Kao, S., Miller, W. H., Delord, J.-P., Gao, B., Planchard, D., Gottfried, M., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.12.109 · Cited by 408
Thistlethwaite, F. C., Gilham, D. E., Guest, R. D., Rothwell, D. G., Pillai, M., Burt, D. J., Byatte, A. J., Kirillova, N., Valle, J. W., Sharma, S. K., et al. (2017) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-017-2034-7 · Cited by 406
Pietanza, M. C., Waqar, S. N., Krug, L. M., Dowlati, A., Hann, C. L., Chiappori, A., Owonikoko, T. K., Woo, K. M., Cardnell, R. J., Fujimoto, J., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.77.7672 · Cited by 399
Self-citationStewart, C. A., Gay, C. M., Xi, Y., Sivajothi, S., Sivakamasundari, V., Fujimoto, J., Bolisetty, M., Hartsfield, P. M., Balasubramaniyan, V., Chalishazar, M. D., et al. (2020) · Nature Cancer · doi:10.1038/s43018-019-0020-z · Cited by 366
Self-citationLok, B. H., Gardner, E. E., Schneeberger, V. E., Ni, A., Desmeules, P., Rekhtman, N., de Stanchina, E., Teicher, B. A., Riaz, N., Powell, S. N., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1040 · Cited by 344
Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses
Cañadas, I., Thummalapalli, R., Kim, J. W., Kitajima, S., Jenkins, R. W., Christensen, C. L., Campisi, M., Kuang, Y., Zhang, Y., Gjini, E., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0116-5 · Cited by 312
Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition
Murai, J., Feng, Y., Yu, G. K., Ru, Y., Tang, S.-W., Shen, Y., & Pommier, Y. (2016) · Oncotarget · doi:10.18632/oncotarget.12266 · Cited by 297
Zhang, W., Girard, L., Zhang, Y.-A., Haruki, T., Papari-Zareei, M., Stastny, V., Ghayee, H. K., Pacak, K., Oliver, T. G., Minna, J. D., et al. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.02.02 · Cited by 263
Self-citationCombination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer
Farago, A. F., Yeap, B. Y., Stanzione, M., Hung, Y. P., Heist, R. S., Marcoux, J. P., Zhong, J., Rangachari, D., Barbie, D. A., Phat, S., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0582 · Cited by 238
Stewart, C. A., Tong, P., Cardnell, R. J., Sen, T., Li, L., Gay, C. M., Masrorpour, F., Fan, Y., Bara, R. O., Feng, Y., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15338 · Cited by 227
Self-citationSTING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype
Della Corte, C. M., Sen, T., Gay, C. M., Ramkumar, K., Diao, L., Cardnell, R. J., Rodriguez, B. L., Stewart, C. A., Papadimitrakopoulou, V. A., Gibson, L., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.01.009 · Cited by 180
Self-citationSato, T., Kaneda, A., Tsuji, S., Isagawa, T., Yamamoto, S., Fujita, T., Yamanaka, R., Tanaka, Y., Nukiwa, T., Marquez, V. E., et al. (2013) · Scientific Reports · doi:10.1038/srep01911 · Cited by 178
MYC-Driven Small-Cell Lung Cancer is Metabolically Distinct and Vulnerable to Arginine Depletion
Chalishazar, M. D., Wait, S. J., Huang, F., Ireland, A. S., Mukhopadhyay, A., Lee, Y., Schuman, S. S., Guthrie, M. R., Berrett, K. C., Vahrenkamp, J. M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-4140 · Cited by 174
Simpson, K. L., Stoney, R., Frese, K. K., Simms, N., Rowe, W., Pearce, S. P., Humphrey, S., Booth, L., Morgan, D., Dynowski, M., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-0046-2 · Cited by 173
Polley, E., Kunkel, M., Evans, D., Silvers, T., Delosh, R., Laudeman, J., Ogle, C., Reinhart, R., Selby, M., Connelly, J., et al. (2016) · Journal of the National Cancer Institute · doi:10.1093/jnci/djw122 · Cited by 169
Owonikoko, T. K., Niu, H., Nackaerts, K., Csőszi, T., Ostoros, G., Márk, Z., Baik, C. S., Joy, A. A., CHOUAID, C., Jaime, J. C., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.10.013 · Cited by 162
Self-citationVenetoclax Is Effective in Small-Cell Lung Cancers with High BCL-2 Expression
Lochmann, T. L., Floros, K. V., Naseri, M., Powell, K. M., Cook, W., March, R. J., Stein, G. T., Greninger, P., Maves, Y. K., Saunders, L. R., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1606 · Cited by 134
Dotan, E., Cohen, S. J., Starodub, A., Lieu, C. H., Messersmith, W. A., Simpson, P. S., Guarino, M. J., Marshall, J. L., Goldberg, R. M., Hecht, J. R., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.9011 · Cited by 124
Paik, P. K., Rudin, C. M., Pietanza, M. C., Brown, A. B., Rizvi, N. A., Takebe, N., Travis, W. D., James, L. P., Ginsberg, M. S., Juergens, R. A., et al. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.05.005 · Cited by 100
Cardnell, R. J., Li, L., Sen, T., Bara, R. O., Tong, P., Fujimoto, J., Ireland, A. S., Guthrie, M. R., Bheddah, S., Banerjee, U., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.20621 · Cited by 91
Self-citationImmunotherapy for small cell lung cancer: mechanisms of resistance
Hamilton, G., & Rath, B. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1592155 · Cited by 85
Whalen, K. A., White, B. H., Quinn, J. M., Kriksciukaite, K., Alargova, R. G., Yeung, T. P. A., Bazinet, P., Brockman, A. H., DuPont, M. M., Oller, H. R., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0022 · Cited by 80
Krohn, A., Ahrens, T. D., Yalcin, A., Plönes, T., Wehrle, J., Taromi, S., Wollner, S., Follo, M., Brabletz, T., Mani, S. A., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100249 · Cited by 69
Immune Checkpoint Inhibitors in the Management of Lung Cancer
Zimmermann, S., Peters, S., Owinokoko, T., & Gadgeel, S. M. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_201319 · Cited by 60
Böttger, F., Semenova, E. A., Song, J., Ferone, G., van der Vliet, J., Cozijnsen, M., Bhaskaran, R., Bombardelli, L., Piersma, S. R., Pham, T. V., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.05.057 · Cited by 60
White, B. H., Whalen, K. A., Kriksciukaite, K., Alargova, R. G., Yeung, T. P. A., Bazinet, P., Brockman, A. H., DuPont, M. M., Oller, H. R., Lemelin, C.-A., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b02036 · Cited by 57
Sharkey, R. M., Govindan, S. V., Cardillo, T. M., Donnell, J., Xia, J., Rossi, E. A., Chang, C., & Goldenberg, D. M. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0442 · Cited by 35
Gay, C. M., Tong, P., Cardnell, R. J., Sen, T., Su, X. H., Ma, J., Bara, R. O., Johnson, F. M., Wakefield, C., Heymach, J. V., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1129 · Cited by 22
Self-citationTargeting MICA with therapeutic antibodies for the treatment of cancer
Bonnafous, C., Péri, V., Trichard, S., Perrot, I., Cornen, S., Thielens, A., Breso, V., Morel, Y., Rossi, B., Paturel, C., et al. (2013) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-1-s1-p41 · Cited by 5
Cited by
Immunotherapies for hepatocellular carcinoma
Llovet, J. M., Castet, F., Heikenwalder, M., Maini, M. K., Mazzaferro, V., Pinato, D. J., Pikarsky, E., Zhu, A. X., & Finn, R. S. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00573-2 · Cited by 1,843
The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015
Nicholson, A. G., Tsao, M. S., Beasley, M. B., Borczuk, A. C., Brambilla, E., Cooper, W. A., Dacic, S., Jain, D., Kerr, K. M., Lantuejoul, S., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.11.003 · Cited by 1,554
Chan, J. M., Quintanal-Villalonga, Á., Gao, V. R., Xie, Y., Allaj, V., Chaudhary, O., Masilionis, I., Egger, J., Chow, A., Walle, T., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.09.008 · Cited by 434
Self-citationMegyesfalvi, Z., Gay, C. M., Popper, H., Pirker, R., Ostoros, G., Heeke, S., Lang, C., Hoetzenecker, K., Schwendenwein, A., Boettiger, K., et al. (2023) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21785 · Cited by 369
Self-citationDurvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer
Cheng, Y., Spigel, D. R., Cho, B. C., Laktionov, K. K., Fang, J., Chen, Y., Zenke, Y., Lee, K. H., Wang, Q., Navarro, A., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2404873 · Cited by 358
Self-citation
Metadata
- Authors
- Gay, C. M., Stewart, C. A., Park, E. M., Diao, L., Groves, S. M., Heeke, S., Nabet, B. Y., Fujimoto, J., Solis, L. M., Lu, W., Xi, Y., Cardnell, R. J., Wang, Q., Fabbri, G., Cargill, K. R., Vokes, N. I., Ramkumar, K., Zhang, B., Della Corte, C. M., Robson, P., Swisher, S. G., Roth, J. A., Glisson, B. S., Shames, D. S., Wistuba, I. I., Wang, J., Quaranta, V., Minna, J., Heymach, J. V., & Byers, L. A.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2021-03
- Volume
- 39
- Issue
- 3
- Pages
- 346-360.e7
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W3124749091
- Cited by
- 962
- References
- 62
- FWCI
- 49.41
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.